ANCA-associated vasculitis combined with coexisting Aspergillus fumigatus and Mycobacterium avium complex infections: a case report Authors: Xinyu Li, Huai Li, Jianping Ren, Jianping Xiao, Deguang Wang, Xuerong Wang Published: 2025 ABSTRACT AbstractBackgroundExisting studies indicate that infection may serve as both initiators and accelerators in the pathogenesis of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) through multiple immunopathological pathways. We report a rare case of AAV combined with two fatal infections of Aspergillus fumigatus and Mycobacterium avium complex (MAC), in which a successful clinical outcome was achieved.Case presentationA 67-year-old female with a history of bronchiectasis was admitted due to poor appetite and fatigue, along with newly identified renal insufficiency. Her serum creatinine levels progressively increased, and urinalysis revealed hematuria and proteinuria. A clinical diagnosis of Aspergillus fumigatus and Mycobacterium avium complex (MAC) infections was made based on the combination of high-resolution computed tomography (HRCT) imaging, results of next-generation sequencing (NGS) in bronchoalveolar lavage fluid (BALF), and serological tests, taking into account the pre-existing bronchiectasis. AAV was diagnosed by serum test and kidney biopsy. Treatment included anti-fungal therapy, glucocorticoids, plasma exchange, and immunoglobulin pulses, without immunosuppressants. The patient’s lung infection and renal function improved remarkably, but dissemination of the MAC infection occurred. Consequently, we added anti-MAC therapy. Along with the improvement of the lung lesion, the AAV also achieved complete remission without relapse during follow-up.ConclusionThis case highlights the novelty of the simultaneous occurrence of AAV, invasive aspergillosis, and MAC infection. We hypothesize that chronic infections in the context of bronchiectasis may have acted as a trigger for ANCA production and the subsequent development of vasculitis. Further investigations are necessary to determine whether the infection acts as a trigger or an accompanying phenomenon.Clinical trialNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12337-9.Keywords: Anti-neutrophil cytoplasmic antibody, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Aspergillus fumigatus, Mycobacterium avium complex, Infection Background Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a category of systemic autoimmune vasculitis characterized by fibrinoid necrosis of small vessels. It is defined by the presence of autoantibodies against neutrophil cytoplasmic antigens, specifically proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA) [1]. AAV is classified into microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [2]. Under the treatment strategy of glucocorticoids combined with immunosuppressive agents, infection becomes a major complication and one of the leading causes of early death in the treatment of AAV. In addition, infection can induce and exacerbate AAV through various mechanisms, and many studies have reported various infections leading to secondary AAV [3]. For instance, several studies reported AAV secondary to pulmonary infections from various pathogens with renal involvement including the Aspergillus and Mycobacterium avium complex (MAC) infections [4]. However, combination of AAV with infection of both the above-mentioned pathogens has not been reported. We describe here the first case of MPA combined with infection of the two rare pathogens Aspergillus fumigatus and MAC and carry out a review of previous relevant studies. This discussion will focus on the characteristics of the case, as well as the correlation between the infection caused by the two pathogens and AAV. Case presentation A 67-year-old Chinese female farmer was admitted to our hospital with poor appetite, generalized weakness, and weight loss. She had a history of bronchiectasis without treatment (Supplementary Fig. 1). She denied a history of hypertension and other diseases, or any medication use. One month earlier, the patient underwent an endoscopic polypectomy in the Department of Gastroenterology, with a baseline serum creatinine level of 0.88 mg/dL (normal 0.5–0.9). Following discharge, she continued to experience poor appetite, accompanied by intermittent fever. She was subsequently rehospitalized. The urinalysis revealed hematuria and proteinuria, and the serum creatinine level was 1.71 mg/dL, leading to her transfer to Department of Nephrology. Physical examination was unremarkable except for an anemic appearance and a slender build, with body mass index of 18.48 kg/m². Laboratory data on admission are shown in Table 1. Chest high-resolution computed tomography (HRCT) showed bronchiectasis with infection in parts of both lungs, more pronounced in the middle and inferior lobes of the right lung (Fig. 1A). Sputum culture was not performed as the patient did not have a productive cough. The reverse transcriptase-polymerase chain reaction (RT-PCR) test for COVID-19, performed on a nasopharyngeal swab, was negative. The results of next-generation sequencing (NGS) in bronchoalveolar lavage fluid (BALF) revealed the presence of both Aspergillus fumigatus (with a sequence count of 5925 and a relative abundance of 17.8%) and MAC (with a sequence count of 104 and a relative abundance of 0.32%). BALF serology tests revealed elevated (1,3)-β-D-glucan (G test) and galactomannan (GM test) levels at 411.9 pg/mL and 0.6 pg/mL, respectively (normal < 90 pg/mL and < 0.5 pg/mL). Table 1Laboratory data on admissionParametersValueReference Range Urine analysis Specific gravity1.0121.003–1.030pH5.04.5–8.0Protein3+NegativeRBC (/µL)530.60–30.7Microalbumin (mg/g)275.00.0–30.0NAG (mg/g)29.60.0–12.0α1-MG (mg/g)51.30.0–12.0β2-MG (mg/g)2.20.0–0.2UTP (mg/24 h)1244.60.0–150 Complete blood count WBC (×109/L)4.93.5–9.5RBC (×109/L)2.953.80–5.10Hb (g/L)86.0115–150PLT(×109/L)101.0125–350 Blood chemistry TP (g/L)60.765.0–85.0ALB (g/L)35.640.0–55.0Scr (mg/dL)1.710.5–0.9BUN (mmol/L)8.943.10–8.80CRP (mg/L)31.50.0–6.0PCT (ng/mL)0.40.0–0.1 Immunology tests p-ANCAPositiveNegativeAnti-MPOPositiveNegativec-ANCANegativeNegativeAnti-PR3NegativeNegativeSemi-quantitativep-ANCA1:80< 20Titer of MPO-Ab(RU/ml)> 600< 20Anti-NuclearNegativeNegativeAnti-GBMNegativeNegativeC3 (g/L)1.060.83–1.77C4 (g/L)0.180.16–0.38 Microbiological tests COVID-19 RT-PCRNegativeNegativeBALF G Test (pg/mL)411.9< 90BALF GM Test (pg/mL)0.6< 0.5BALF bacterial cultureNo growthNo growthAbbreviations: RBC, red blood cell; NAG, N-acetyl-β-D-glucosaminidase; ɑ1-MG, ɑ1-microglobulin; β2-MG, β2-microglobulin; UTP, urinary total protein; WBC, white blood cell; Hb, hemoglobin; PLT, platelets count; TP, total protein; ALB, albumin; Scr, serum creatinine; BUN, blood urine nitrogen; CRP, C-reactive protein; PCT, procalcitonin; p-ANCA, perinuclear anti-neutrophil cytoplasmic antibody; MPO, myeloperoxidase; c-ANCA, cytoplasmic ANCA; PR3, proteinase 3; GBM, glomerular basement membrane; C3, Complement C3; C4, Complement C4; COVID-19, coronavirus-19; RT-PCR: reverse transcriptase-polymerase chain reaction; BALF, bronchoalveolar lavage fluid; G test, (1,3)-β-D-glucan test; GM test, galactomannan test Laboratory data on admission Semi-quantitative p-ANCA Titer of MPO-Ab (RU/ml) Abbreviations: RBC, red blood cell; NAG, N-acetyl-β-D-glucosaminidase; ɑ1-MG, ɑ1-microglobulin; β2-MG, β2-microglobulin; UTP, urinary total protein; WBC, white blood cell; Hb, hemoglobin; PLT, platelets count; TP, total protein; ALB, albumin; Scr, serum creatinine; BUN, blood urine nitrogen; CRP, C-reactive protein; PCT, procalcitonin; p-ANCA, perinuclear anti-neutrophil cytoplasmic antibody; MPO, myeloperoxidase; c-ANCA, cytoplasmic ANCA; PR3, proteinase 3; GBM, glomerular basement membrane; C3, Complement C3; C4, Complement C4; COVID-19, coronavirus-19; RT-PCR: reverse transcriptase-polymerase chain reaction; BALF, bronchoalveolar lavage fluid; G test, (1,3)-β-D-glucan test; GM test, galactomannan test Chest HRCT scan findings. (A) CT on the 1st day of admission suggested bronchiectasis with infection in the middle and lower lobes of the right lung were prominent. (B) CT on the 71st day of admission showed a new dissemination lesion of MAC. (C-D) The lesions were significantly absorbed and improved after anti-fungal and anti-MAC treatment on the 131st day of admission. Abbreviations: HRCT, High-resolution computed tomography; MAC, Mycobacterium avium complex Upon transfer to our department, her serum creatinine rapidly increased to 5.54 mg/dL and the MPO-ANCA test was positive. Then, kidney biopsy was performed (Fig. 2). Light microscopy showed that among 16 glomeruli in the specimen, 2 glomerulus exhibited global sclerosis, 7 glomeruli presented fibrocellular crescents, 1 glomeruli had small cellular crescent, and 1 glomeruli had small fibrocellular crescent. The renal interstitium exhibited multifocal infiltration of inflammatory cells, primarily lymphocytes and monocytes. Immunofluorescence microscopy revealed pauci-immune glomerulonephritis and electron microscopy manifested no exact electron dense deposits. Thus, she was diagnosed with MPA, bronchiectasis with infection, invasive pulmonary aspergillosis (IPA), and pulmonary MAC infection. Although a definitive diagnosis of IPA was lacking, a clinical possible diagnosis of IPA was made based on the following factors: (1) the presence of pre-existing bronchiectasis as a high-risk condition; (2) cavitary changes on HRCT suggesting IPA; (3) the positive GM test in the BALF; and (4) the high sequence count of Aspergillus fumigatus by NGS in the BALF [5–7]. A diagnosis of nontuberculous mycobacterial (NTM) pulmonary disease was supported by the presence of bronchiectasis as a host factor and the high sequence count of MAC by NGS in the BALF, consistent with established diagnostic guidelines [8, 9]. Due to the patient’s concurrent rare mixed lung infection of the two fatal pathogens, immunosuppressants were not administered. Consultation from the respiratory department considered the lesion to be primarily due to Aspergillus, with a low sequence count of MAC, which is an indolent bacterium. Accordingly, a strategy of watchful waiting without immediate anti-MAC therapy was adopted as the initial management [10]. Therefore, in addition to anti-fungal treatment with voriconazole (0.2 g every 12 h), the patient received methylprednisolone (40 mg daily) and underwent six sessions of plasma exchange (PE) therapy. Moreover, intravenous immunoglobulin (IVIg) was used 15 g once daily for 3 days. Forty days after readmission, the patient manifested amelioration of pulmonary infection, a partial recovery of renal function, and a slight decline of MPO titers from > 600 RU/mL to 477 RU/mL. Kidney biopsy findings. (A) Light microscopy showing the formation of a fibrocellular crescent. Focal tubular atrophy, interstitial fibrosis, interstitial edema, widening, and multifocal inflammatory cell infiltration (mainly lymphocytes and monocytes) can be seen (Hematoxylin and eosin stain, original magnification 200×). (B) Fibrocellular crescent is visible (Masson’s trichrome staining, original magnification 200×) However, after two months of anti-fungal treatment, new miliary changes emerged in the inferior lobe of the right lung, along with radiographic progression of MAC infection (Fig. 1B). Notably, no accompanying skin lesions or other systemic signs were observed, which was consistent with a diagnosis of NTM pulmonary disease. Additional treatment for MAC including azithromycin (0.5 g thrice weekly), ethambutol (0.75 g daily), and ciprofloxacin (0.25 g daily) was administered. Two months later, because of the side effects of these prescriptions, the patient experienced a significant decrease in appetite and numbness in the limbs. Meanwhile, the lung lesions on the right side improved (Fig. 1C and D). The favorable pulmonary response to targeted anti-fungal and anti-MAC therapy further validated the clinical diagnosis of this rare dual infection. The MPO-ANCA titer subsequently became negative concomitant with the resolution of the pulmonary infection. Following a multidisciplinary consultation, the treatment for MAC and Aspergillus fumigatus was discontinued. The patient’s above-mentioned symptoms have improved significantly, with the steroid dose gradually reduced to 5 mg daily for maintenance. Outpatient follow-up revealed negative MPO, and urine protein and urine erythrocytes turned negative, along with stabilized renal function. The clinical course of the patient was documented in detail (Fig. 3). Clinical course and treatment of the present case. Abbreviations: MP, methylprednisolone; Pred, prednisone; PE, plasma exchange; IVIg, intravenous immunoglobin; AZM, azithromycin; EB, ethambutol; CIP, ciprofloxacin; VCZ, voriconazole; Scr, serum creatinine; MPO-Ab, Myeloperoxidase Antibody Discussion AAV is a necrotizing small-vessel vasculitis characterized by the presence of ANCA and multiorgan inflammation. It is strongly associated with ANCA directly to either PR3 or MPO. PR3-ANCA is predominant in GPA and MPO-ANCA in MPA. The association between infections, formation of ANCA and ANCA-mediated disease has been known for decades [11]. The proposed mechanisms of ANCA formation in infectious episodes include autoantigen complementarity, molecular mimicry, epigenetics, neutrophil extracellular traps (NETs), and Toll-like receptors [12]. Infections may promote ANCA production by inducing neutrophil activation and the formation of NETs. NETs are composed of chromatin and granule proteins, including PR3 and MPO, and the subsequent exposure of this autoantigen may trigger the generation of autoantibodies, ultimately leading to vasculitis. If infections persist, the ongoing stimulation may lead to sustained production of ANCA and a series of immune cascade reactions, potentially resulting in secondary AAV with irreversible pathological damage to tissues [13]. MPO-ANCA production does occur following infections and can lead to development of small vessel vasculitis or glomerulonephritis; pathogens including Mycobacterium spp., Coccidioides spp., Rickettsia rickettsii, Staphylococcus spp., EBV, CMV, and Dengue virus, have been reported [14]. AAV following aggravation of pulmonary Aspergillosis is very rare. Morita et al. [15] reported a case of a 74-year-old man, who had aggravation of chronic pulmonary aspergillosis that worsened within a month and developed severe kidney failure requiring hemodialysis. Renal biopsy revealed atypical ANCA-associated nephritis characterized by absence of cellular crescents, extensive arteritis involving vessels of varying sizes. Combination treatment with anti-fungal agents, IVIg, PE, and steroids led to complete resolution of the vasculitis. The specific histological findings and the good response to treatments suggest that pulmonary aspergillosis might trigger vasculitis through induction of ANCA-antigen expression. MAC is the most common organism in patients with pulmonary nontuberculous mycobacteria (NTM), while MAC infection is usually slowly progressive, and affected patients often receive no treatment if their symptoms are trivial [16]. To our knowledge, there are five published case reports detailing the diagnosis, management, and outcomes of comorbid AAV and MAC infection. We made a summary of these cases in Table 2 [17–21]. Oda et al. provide key evidence linking NTM infection to AAV development, potentially through ANCA production, especially MPO-ANCA. Their study, one of the largest to date, found that 71.4% (5/7) of ANCA-positive pulmonary NTM patients progressed to AAV, predominantly manifesting as MPA [22]. However, the mechanism by which MAC induces ANCA production is not fully clarified. Table 2Summary of to-date published case reports on MAC infection combined with AAVAuthorsCountryAge/genderPrevious medical historyClinical symptomsAAVRenal biopsyAnti-infective treatmentVasculitis treatmentOutcomeShuichi Asano et al., [17]Japan73/FUntreated pulmonary MAC infectionFever, polyarthritis, purpura, and RPGNMPAIRGN accompanied by MPO-ANCA related, severe, necrotizing crescentic glomerulonephritisCAM, RFP, EBGSPartial renal function recovery with improved AAV and infectionChaiamnuay et al., [18]USA75/FHypertension and chronic kidney diseaseChronic cough, arthralgias, hemoptysis, dyspnea, new purpuric skin lesions, and worsening renal functionGPANoneCPFX, AZM, EBGS, CYC, AZAImprovement of renal function and AAVMikiya Kato et al., [19]Japan65/FNTM infection without treatment and polyarteritis nodosaFever, general malaise, and RPGNMPACrescentic glomerulonephritis with linear deposits of IgG and C3c along with the GBM and interstitial inflammationNoneGS, PEThe anti-GBM antibody and MPO-ANCA antibody titer decreased, renal function did not recover and remained on hemodialysisYutakaTomishima et al., [20]Japan80/FBronchiectasisHearing loss, tinnitus, and weight lossMPANoneCAM, RFP, EBNoneHearing returned to normal levels and the titer of MPO-ANCA normalizedRyuichi Yoshii et al., [21]Japan72/MNTM pulmonary disease and bronchiectasisFever, arthralgia, and acute kidney injuryMPA7% of glomeruli exhibited global sclerosis, 60% showed cellular crescents in Bowman’s space and fbrinoid necrosis on glomerulartuftsCAM, RFP, EBGS, PE, RTXCreatinine and MPO-ANCA decreasedOur caseChina67/FBronchiectasisPoor appetite, fatigue, and weight lossMPA12.5% of glomeruli exhibited global sclerosis, 50% showed fibrocellular crescentsVCZ, AZA, EB, CIPGS, PE, IVIgImprovement of renal function, negative MPO, urine protein, and urine erythrocytesAbbreviations: MAC, Mycobacterium avium complex; AAV, anti-neutrophil cytoplasmic antibody associated vasculitis; F, female; M, male; NTM, nontuberculous mycobacterium; MPA, microscopic polyangiitis; CAM, clarithromycin; RFP, rifampicin; EB, ethambutol; GS, glucocorticosteroid; PE, plasma exchange; RTX, rituximab; MPO, myeloperoxidase; RPGN, rapidly progressive glomerulonephritis; GBM, anti-glomerular basement membrane antibody; IRGN, infection-related glomerulonephritis; GPA, granulomatosis with polyangiitis; CPFX, ciprofoxacin; AZM, azithromycin; CYC, cyclophosphamide; AZA, azathioprine; VCZ, voriconazole; CIP, ciprofloxacin; IVIg, intravenous immunoglobin Summary of to-date published case reports on MAC infection combined with AAV Abbreviations: MAC, Mycobacterium avium complex; AAV, anti-neutrophil cytoplasmic antibody associated vasculitis; F, female; M, male; NTM, nontuberculous mycobacterium; MPA, microscopic polyangiitis; CAM, clarithromycin; RFP, rifampicin; EB, ethambutol; GS, glucocorticosteroid; PE, plasma exchange; RTX, rituximab; MPO, myeloperoxidase; RPGN, rapidly progressive glomerulonephritis; GBM, anti-glomerular basement membrane antibody; IRGN, infection-related glomerulonephritis; GPA, granulomatosis with polyangiitis; CPFX, ciprofoxacin; AZM, azithromycin; CYC, cyclophosphamide; AZA, azathioprine; VCZ, voriconazole; CIP, ciprofloxacin; IVIg, intravenous immunoglobin While co-infections with Aspergillus and MAC can occur in patients with structural lung diseases, the coexistence of AAV complicated by coinfection with two uncommon pathogens is very rare. To our knowledge, our case represents the first reported instance of AAV combined with Aspergillus fumigatus and MAC infections, where a favorable prognosis was achieved. The patient in our case had a long history of bronchiectasis and presented with poor appetite, fatigue, and weight loss. During the disease course, the patient developed pulmonary infections caused by two rare pathogens, rapidly progressive glomerulonephritis, and high titers of MPO-ANCA. Kidney biopsy findings were consistent with typical AAV-related kidney injury. The first possibility is that infections might have an etiologic or precipitating role in the development of AAV. We hypothesize that in our case, one probable mechanism is molecular mimicry, whereby persistent exposure to microbial antigens (from both Aspergillus fumigatus and MAC) may break immune self-tolerance, leading to the production of ANCA that cross-react with native neutrophil antigens like MPO. The close temporal relationship between the pulmonary infection and the acute onset of rapidly progressive glomerulonephritis with high MPO-ANCA titers suggests a potential pathogenic link. Furthermore, chronic infection is a potent inducer of NETs formation. NETs formation characterizes a unique type of neutrophil-related cell death named NETosis. Excessive NETosis, of which the clearance is impaired in the presence of bronchiectasis, can lead to prolonged exposure of MPO and other autoantigens to the immune system. This sustained exposure may promote ANCA production and trigger vasculitic lesions, as has been proposed in MPO-AAV pathogenesis [14]. It is notable that in our case systemic vasculitis improved rapidly with a treatment strategy based on anti-infective agents, moderate-dose glucocorticoids, plasma exchange, and IVIg, which did not include aggressive immunosuppressive therapy such as high-dose glucocorticoids, cyclophosphamide or rituximab. During follow-up, the patient achieved complete remission of vasculitis after the infection was controlled. No relapse occurred after the glucocorticoids were tapered and discontinued. The MPO-ANCA titer dynamics, though not frequently monitored due to cost considerations, still provided valuable clinical insights. The titer was initially elevated, showed a slight decrease prior to MAC progression while remaining abnormally high, and finally normalized only after the infections resolved. Although this pattern did not strictly synchronize with the disease activity, the eventual normalization of the titer coinciding with the clinical improvement of both infection and vasculitis supports the potential role of infection in triggering autoimmunity. This clinical course, combined with the observed serological trend, while not conclusive, lends further support to the hypothesis that the chronic infections acted as a primary trigger in this case of AAV. The second possible explanation is that the patient’s symptoms may arise from a coincidental overlap of two independent disease processes: infectious and autoimmune. This case could be interpreted as a rare co-occurrence of AAV and dual infection in a patient with preexisting chronic bronchiectasis. An additional possibility is that patients with AAV may be predisposed to infection in a patient with pre-existing bronchiectasis. Therefore, further investigation is warranted to determine whether the infection served as a trigger or was merely a coexisting phenomenon in this case. High-dose glucocorticoids, cyclophosphamide, and rituximab have been recommended by the guidelines as the main AAV treatment strategy [23]. IVIg and PE are occasionally used as adjunct therapies [24, 25]. The coexistence of Aspergillus and MAC infections is very rare and predominantly occurs in immunocompromised hosts. This condition carries a poor prognosis, with most affected individuals facing a high mortality rate [26]. Previous studies have suggested the potential efficacy of IVIg as an initial immunosuppressive therapy for patients with MPA and its clinical benefit when used as an adjunct therapy in addition to its suppressive effect on active infection [27]. Therefore, for the initial induction of remission therapy in our case we prescribed a relatively low dose of glucocorticoids, PE, and IVIg, in addition to anti-fungal therapy. The patient’s symptoms and renal function improved rapidly, but dissemination of MAC infection occurred during the treatment. Consequently, we added anti-MAC therapy based on multidisciplinary consultation, without the use of immunosuppressants. The relationship between infections and AAV is intricate. When it is difficult to distinguish AAV from infection, infection-related evidence should be sought from clinical manifestations, serology, infectious disease findings, and tissue biopsies to rule out infection. If ANCA positivity is detected in the serum of infected patients, a comprehensive evaluation of multiple autoantibodies and complement levels should be performed. For such patients, given that immunosuppressive therapy may exacerbate infections, anti-infection therapy should be the primary approach. Clinical manifestations, pathology, and other factors should be considered to determine the necessity of immunosuppressive therapy. Advancements in diagnostic tools and a deeper understanding of pathogens will help elucidate the close relationship between infections and AAV, facilitating better treatment strategies. In conclusion, this is the first case reporting AAV combined with Aspergillus fumigatus and MAC infections. Combination treatment with anti-fungal and MAC agents, glucocorticoids, PE, and IVIg, led to complete resolution of the vasculitis. This case highlights the possibility that Aspergillus fumigatus and MAC infections might trigger or exacerbate autoimmunity, leading to AAV. Further studies are required to explore the possible connection between AAV and infections. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1: Fig. 1 Baseline chest HRCT findings. HRCT from 2021 revealed chronic bronchiectasis in both lungs, which was more pronounced in the right middle and lower lobes. HRCT, High-resolution computed tomography Acknowledgements We acknowledge the contributions of the colleagues in the Second Affiliated Hospital of Anhui Medical University that aided the efforts of the authors. Abbreviations Anti-neutrophil cytoplasmic antibody-associated vasculitis Ant-ineutrophil cytoplasmic antibody Bronchoalveolar lavage fluid Coronavirus-19 Eosinophilic granulomatosis with polyangiitis (1,3)-β-D-glucan test Galactomannan test Granulomatosis with polyangiitis High-resolution computed tomography Invasive pulmonary aspergillosis Intravenous immunoglobulin Mycobacterium avium complex Microscopic polyangiitis Myeloperoxidase-antineutrophil cytoplasmic antibody Neutrophil extracellular traps Next-generation sequencing Nontuberculous mycobacteria Plasma exchange Proteinase 3-antineutrophil cytoplasmic antibody Reverse transcriptase-polymerase chain reaction Author contributions XL drafted the manuscript. XW and DW revised it. HL, JR and JX directly contributed to the patient care. XW supervised the case. All authors approved the final manuscript. Funding This work was supported by grants from the Natural Science Research Program of Anhui Provincial Universities (KJ2021A0314), Health Research Program of Anhui Province (AHWJ2023A20134), Clinical Research and Cultivation Program of the Second Affiliated Hospital of Anhui Medical University (2020LCYB06), Research Fund of Anhui Institute of translational medicine (2023zhyx-B09). Data availability The datasets are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The publication of the case was approved by the Ethics committee of Second Affiliated Hospital of Anhui Medical University. A written and signed consent to publish the information from the patient prior to submission was obtained. Consent for publication Written informed consent was obtained from the patient for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xinyu Li and Huai Li contributed equally to this work. Contributor Information Deguang Wang, Email: wangdeguang@ahmu.edu.cn. Xuerong Wang, Email: xuerwang215@yeah.net. References Associated Data Supplementary Materials Supplementary Material 1: Fig. 1 Baseline chest HRCT findings. HRCT from 2021 revealed chronic bronchiectasis in both lungs, which was more pronounced in the right middle and lower lobes. HRCT, High-resolution computed tomography Data Availability Statement The datasets are available from the corresponding author on reasonable request.